Metabolites have been referred to as proximal reporters of disease because clinical chemistry laboratory results frequently show that their abundances in biological specimens are frequently directly related to pathogenic mechanisms (Gerszten and Wang 2008). Between the initial discovery of a disease marker, its validation in human trials, and its routine implementation as a clinical test, historically, often a decade or more could elapse. We must hasten the discovery of precise disease markers, drug pharmacodynamics, and metabolite profiles linked to the external environment and their associations with disease risk in order to fully realise the potential of precision medicine. The discovery and validation of metabolic disease indicators can happen more quickly thanks to current metabolomics technologies.
Read More:
https://bloggerthrive.blogspot.com/2022/11/metabolomics-is-biological-study-of.html
